Estadístiques de CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma
Visites totals
| views | |
|---|---|
| CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma | 3 |
Visites totals per mes
| views | |
|---|---|
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
| May 2025 | 3 |
| June 2025 | 0 |
Visites al fitxer
| views | |
|---|---|
| Hontecillas_fi_cd8.pdf | 8 |